Reply
We are grateful for the comments of Dr. Thombs and colleagues.
In our recent study we set out to examine the effects of the timing of assessment of depression on mortality after myocardial infarction (MI) (1) . We showed that depression before MI, whether chronic or not, does not increase cardiac mortality. This was a surprise to us because we anticipated that pre-MI depression, which was associated with chronic social difficulties (2) and likely to be persistent (3), would be related to increased mortality after MI. We have published this paper to make it clear that this is not the case. Furthermore, we found that depression present 12 months after MI did not predict subsequent mortality.
We acknowledge that our study alone does not provide direct evidence for a window of effect for depression predicting increased mortality. However, if we contrast our findings with those studies showing an association of depression in the days or weeks after MI with post-MI mortality, it seems likely that it is those people who develop depression in the period immediately after MI that are at increased risk of cardiac mortality. Patients developing depression after an acute cardiac event have been shown to be at increased risk of dying in previous studies (4, 5) , and we are now looking at this particular question in our own data.
Our negative findings for depression cannot be dismissed as resulting from our statistical methods. We accept the point that the number of independent variables included was large, but our finding was the same in the uncontrolled (univariate) comparison. Furthermore, our findings remained stable if we used backward elimination of variables, so that the number of independent variables in the final model was few (hazard ratio [HR] for depression ϭ 0.86, p ϭ 0.60) or if we performed our analyses using fewer variables (e.g., age, gender, educational level, degree of cardiac dysfunction, and revascularization procedures (4), HR for depression ϭ 1.02, p ϭ 0.94). Our findings also remained negative when we did not control for medications at discharge (HR for depression ϭ 0.87, p ϭ 0.62).
Our finding that subjects with depression at both baseline and 12 months had an apparent survival advantage is confusing and counterintuitive. We can clarify here that, compared with the remainder, this group was more likely to be female gender (49% vs. 28%) and younger (mean age 45.3 vs. 60.8 years). Controlling for age and gender alone eliminated the association between persistent depression and subsequent mortality (p ϭ 0.97).
The fact that depression that predates the MI and persists through the post-MI period does not predict mortality is extremely important. It supports the suggestion that it is not depression alone that is having the adverse impact on survival but that some additional factor interacts with depression to create this effect (6, 7) . Rather than ignoring the heterogeneity in previous findings, future research should continue to examine possible reasons for this heterogeneity as it may identify vulnerable subgroups and explain how and why depression has this effect on survival. 
*

Eliminating Plaque Angiogenesis
We have read with great interest the article by Kolodgie et al. (1) focusing on elimination of intraplaque angiogenesis. It seems that neovascularization within the vessel wall plays an important role in plaque destabilization, and it is a determinant of vulnerability.
The beneficial effect of statins in patients with atherosclerotic disease is well established. This effect goes beyond lipid lowering, because statins also have other effects, which is why statins are considered pleiotropic. One of these is its effect on angiogenesis. We recently presented that patients on statin treatment have reduced intraplaque angiogenesis in their carotid endarterectomy specimens when compared with patients not receiving this kind of drug (2) . This finding provides a new insight to the statins' pathophysiologic mechanism of action. The fact that it was a cross-sectional, retrospective study without randomization cannot lead us to any causal conclusions about statins and intraplaque angiogenesis. However, there are strong indications favoring that hypothesis. Vascular endothelial growth factor is a well-recognized and potent angiogenetic factor. It is known that pravastatin, but also fenofibrate, reduces vascular endothelial growth factor plasma levels in humans (3) .
These findings raise the question of whether statins are the antiangiogenetic factor for which we are searching. To answer this question, further investigation is needed, and maybe it is time for a randomized trial with standard dose and duration of treatment to test the effect on intraplaque angiogenesis. 
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